<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Diuretic-induced hyperuricemia and gout</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Diuretic-induced hyperuricemia and gout</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Diuretic-induced hyperuricemia and gout</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lisa K Stamp, FRACP, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard H Sterns, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John P Forman, MD, MSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 30, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H532274"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Hyperuricemia is a relatively common finding in people treated with a loop or thiazide diuretic and may, over a period of time, contribute to new-onset gout or recurrence of established gout [<a href="#rid1">1-5</a>]. Diuretics reduce urate excretion by both directly and indirectly increasing urate reabsorption and decreasing urate secretion [<a href="#rid2">2,6-9</a>]; the effect is dose dependent  (<a class="graphic graphic_figure graphicRef69912" href="/d/graphic/69912.html" rel="external">figure 1</a>). Treatment of asymptomatic hyperuricemia is not recommended in most countries. If diuretic-induced gout occurs, it is typically treated with a urate-lowering drug such as <a class="drug drug_general" data-topicid="8439" href="/d/drug information/8439.html" rel="external">allopurinol</a>.</p><p>The pathogenesis, epidemiology, and an overview of treatment of diuretic-induced hyperuricemia and gout are presented in this topic. The pathophysiology, clinical manifestations, diagnosis, and treatment of gout flares as well as the prevention of gout flares are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1673.html" rel="external">"Pathophysiology of gout"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1667.html" rel="external">"Clinical manifestations and diagnosis of gout"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1666.html" rel="external">"Treatment of gout flares"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1672.html" rel="external">"Pharmacologic urate-lowering therapy and treatment of tophi in patients with gout"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/105886.html" rel="external">"Nonpharmacologic strategies for the prevention and treatment of gout"</a>.)</p><p></p><p class="headingAnchor" id="H1"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The proximal tubule is the major site of urate handling; both secretion and reabsorption occur in this segment, with the net effect being reabsorption of most of the filtered urate  (<a class="graphic graphic_figure graphicRef83925" href="/d/graphic/83925.html" rel="external">figure 2</a> and <a class="graphic graphic_figure graphicRef83926" href="/d/graphic/83926.html" rel="external">figure 3</a>) [<a href="#rid2">2,9-17</a>]. Urate enters the proximal tubular cell from peritubular capillary blood through organic anion transporters 1 and 3 (OAT1 and OAT3) located on the basolateral membrane, and is secreted from the cell into the tubular fluid through solute carrier (SLC) family members SLC17A1 and SLC17A3, multidrug resistance protein 4 (MRP4), and ATP-binding cassette G2 (ABCG2) located on the luminal membrane. Urate reabsorption from the tubular fluid into the cell is mediated by urate transporter 1 (URAT1), OAT4, and OAT10, located on the luminal membrane, and from the cell back to the peritubular capillary blood through glucose transporter 9 (GLUT9) located on the basolateral membrane.</p><p>Loop and thiazide diuretics decrease urate excretion by increasing net urate reabsorption; this can occur either by enhanced reabsorption or by reduced secretion [<a href="#rid2">2,6</a>]. Two mechanisms have been proposed as contributing to diuretic-induced hyperuricemia [<a href="#rid2">2,6-8</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A direct effect of diuretics on promoting urate reabsorption by the proximal tubule</p><p class="bulletIndent1"><span class="glyph">●</span>An indirect effect of diuretic-induced volume depletion on increasing urate reabsorption by the proximal tubule</p><p></p><p>The degree of urate retention caused by diuretics is dose dependent  (<a class="graphic graphic_figure graphicRef69912" href="/d/graphic/69912.html" rel="external">figure 1</a>) [<a href="#rid18">18</a>]. This contrasts with the dose response relationship between diuretics and blood pressure, in which 12.5 mg of <a class="drug drug_general" data-topicid="8529" href="/d/drug information/8529.html" rel="external">hydrochlorothiazide</a> (or its equivalent) is often as effective as 50 mg  (<a class="graphic graphic_figure graphicRef61248" href="/d/graphic/61248.html" rel="external">figure 4</a>). (See  <a class="medical medical_review" href="/d/html/3860.html" rel="external">"Use of thiazide diuretics in patients with primary (essential) hypertension"</a>.)</p><p class="headingAnchor" id="H532627"><span class="h2">Direct effect of diuretics</span><span class="headingEndMark"> — </span>Thiazide diuretics selectively enhance urate reabsorption by acting as a counter-ion for urate transport [<a href="#rid7">7</a>]. First, the thiazide enters the proximal tubule cell from the peritubular capillary blood through the anion exchanger, OAT1, on the basolateral membrane. The diuretic is then released into the tubular fluid from the cell by the urate anion exchanger, OAT4, on the luminal membrane, driving reabsorption of urate. Thiazide diuretics also upregulate the sodium-hydrogen exchanger in the proximal tubule, thereby stimulating pH-dependent OAT4 activity [<a href="#rid19">19</a>]. In addition, both thiazide and loop diuretics may inhibit MRP4 on the luminal membrane, reducing secretion of urate into the tubular fluid [<a href="#rid8">8</a>].</p><p class="headingAnchor" id="H532634"><span class="h2">Indirect effect of diuretic-induced volume depletion</span><span class="headingEndMark"> — </span>Volume depletion appears to play an important role in diuretic-induced hyperuricemia since urate retention does not occur if the diuretic-induced fluid losses are replaced [<a href="#rid20">20</a>]. In addition, short- and long-term salt restriction produces significant hyperuricemia, which is reversed by salt loading [<a href="#rid21">21-26</a>]. In various studies, the difference in serum urate between salt restricted and salt loaded subjects was 1 to 1.4 mg/dL [<a href="#rid22">22-26</a>].</p><p>How volume depletion or salt restriction increases net urate reabsorption is unclear [<a href="#rid2">2</a>]. One possible explanation is the parallel relationship between sodium and urate reabsorption in the proximal tubule [<a href="#rid2">2,27</a>]. Urate entry into the cell appears to occur by a variety of anion exchangers  (<a class="graphic graphic_figure graphicRef83926" href="/d/graphic/83926.html" rel="external">figure 3</a>), including urate-hydroxyl and urate-lactate exchangers [<a href="#rid27">27</a>]. Both of these processes are dependent upon sodium transport.</p><p>As an example, sodium-hydrogen exchangers in the luminal membrane are responsible for most of proximal bicarbonate reabsorption. The secretion of hydrogen ions by these transporters makes the cell more alkaline than the tubular lumen. The higher hydroxyl concentration in the cell provides a favorable gradient for hydroxyl exit, which can then drive urate reabsorption. Similarly, sodium-lactate cotransporters in the luminal membrane mediate lactate entry into the cell; this lactate can then be secreted back into the lumen by urate-lactate exchange.</p><p>This indirect relationship between sodium and urate is clinically important because hypovolemia (in part via increased generation of angiotensin II) is associated with an appropriate increase in proximal sodium reabsorption [<a href="#rid28">28</a>]. The rise in the activity of the sodium-hydrogen exchanger in this setting [<a href="#rid28">28</a>] can then lead to increased urate-hydroxyl exchange and therefore enhanced urate reabsorption [<a href="#rid2">2,27</a>].</p><p class="headingAnchor" id="H532422"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Thiazide diuretics are widely used in treatment of hypertension and are inexpensive and efficacious. (See  <a class="medical medical_review" href="/d/html/3860.html" rel="external">"Use of thiazide diuretics in patients with primary (essential) hypertension"</a>.)</p><p>Thiazide and loop diuretics, but not potassium-sparing diuretics [<a href="#rid29">29</a>], are independent risk factors for incident [<a href="#rid3">3,4</a>] and, likely, recurrent [<a href="#rid5">5</a>] gout. In a large prospective cohort of men, for example, approximately 4700 participants without a prior history of gout used diuretics, and nearly 3 percent of these men subsequently developed gout [<a href="#rid3">3</a>]. Compared with men who did not use diuretics, those who did had a 77 percent higher relative risk of developing gout, even after controlling for conventional risk factors for gout such as adiposity, alcohol intake, kidney function, and hypertension. While people with diuretic-induced gout present with similar clinical features as those with primary gout, they tend to be older and have a higher serum urate [<a href="#rid30">30</a>]. In addition, genetic features such as the <em>ABCG2</em> gout risk allele are less frequently present [<a href="#rid30">30</a>]. </p><p class="headingAnchor" id="H2"><span class="h1">OVERVIEW OF TREATMENT AND BENEFITS OF ANGIOTENSIN INHIBITION</span><span class="headingEndMark"> — </span>Treatment of diuretic-induced asymptomatic hyperuricemia is not routinely recommended in most countries, even though the serum urate concentration may exceed 15 mg/dL (0.89 mmol/L) with diuretic therapy (particularly in people with reduced kidney perfusion due to underlying advanced heart failure) [<a href="#rid1">1,31</a>]. These people are not at risk of uric acid precipitation in the tubules (uric acid nephropathy), since the elevation in the serum urate is due to an initial decrease in the rate of urate excretion. Prophylactic treatment with urate-lowering therapy is not warranted to treat an abnormal blood test [<a href="#rid31">31</a>]. (See  <a class="medical medical_review" href="/d/html/1669.html" rel="external">"Asymptomatic hyperuricemia"</a>.)</p><p>A diagnosis of gout is <strong>not</strong> necessarily an indication for discontinuation of the diuretic, particularly if diuretic therapy is required for management of edema. However, if blood pressure control can be effectively and affordably achieved with an appropriate alternative agent, such as an angiotensin inhibitor or a dihydropyridine calcium channel blocker, then the diuretic should be replaced by an alternative agent that is not associated with urate retention. Such an approach can lower urate levels and [<a href="#rid32">32</a>], theoretically, reduce gout risk. (See  <a class="medical medical_review" href="/d/html/3869.html" rel="external">"Choice of drug therapy in primary (essential) hypertension"</a>.)</p><p>Most people with diuretic-induced gout are treated with a urate-lowering drug such as <a class="drug drug_general" data-topicid="8439" href="/d/drug information/8439.html" rel="external">allopurinol</a> (see  <a class="medical medical_review" href="/d/html/1672.html" rel="external">"Pharmacologic urate-lowering therapy and treatment of tophi in patients with gout"</a>). The concomitant use of a urate-lowering agent and a diuretic may require a higher dose of the former to achieve the goal range for serum urate of &lt;6 mg/dL. This combination may impart a higher risk for allopurinol hypersensitivity reactions [<a href="#rid33">33</a>]. However, subsequent studies suggest that carefully titrating the urate-lowering drug dose to achieve the goal urate level is likely <strong>not</strong> associated with a higher risk for this serious adverse event [<a href="#rid34">34,35</a>].</p><p>We agree with the 2020 American College of Rheumatology guidelines for treatment of hyperuricemia in gout that no one commence <a class="drug drug_general" data-topicid="8439" href="/d/drug information/8439.html" rel="external">allopurinol</a> at more than 100 mg daily and that the starting dose be reduced to 50 mg daily in people with stage 4 or 5 chronic kidney disease [<a href="#rid36">36</a>]. The dose should be titrated in increments of 100 mg (or 50 mg) every two to four weeks until target serum urate is achieved (&lt;6 mg/dL [0.36 mmol/L]). Gout flares are common in the early months of urate-lowering therapy, and flare prophylaxis, with <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a>, a nonsteroidal antiinflammatory drug (NSAID), or <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>, is recommended as cotherapy with the urate-lowering therapy. (See  <a class="medical medical_review" href="/d/html/1672.html" rel="external">"Pharmacologic urate-lowering therapy and treatment of tophi in patients with gout", section on 'Approach to drug therapy'</a> and  <a class="medical medical_review" href="/d/html/1672.html" rel="external">"Pharmacologic urate-lowering therapy and treatment of tophi in patients with gout", section on 'Prophylaxis during initiation of urate-lowering therapy'</a>.)</p><p>People with gout who are receiving diuretics for comorbidities should be encouraged to adhere to the prescribed diuretic dose since many gout flares occur in the setting of changes in serum urate levels that accompany intermittent diuretic use [<a href="#rid5">5</a>].</p><p class="headingAnchor" id="H3"><span class="h2">Benefits of angiotensin inhibition and losartan</span><span class="headingEndMark"> — </span>Among people with hypertension, the concurrent administration of an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB) can minimize the diuretic-induced rise in serum urate concentration [<a href="#rid37">37-39</a>]. This has been thought to be mediated by reversal of the stimulatory effect of angiotensin II on proximal sodium and urate reabsorption. (See <a class="local">'Indirect effect of diuretic-induced volume depletion'</a> above.)</p><p>In addition, <a class="drug drug_general" data-topicid="9574" href="/d/drug information/9574.html" rel="external">losartan</a> may have a more direct uricosuric effect, thereby inhibiting urate reabsorption and lowering the serum urate concentration. This hypothesis is supported by the following observations:</p><p class="bulletIndent1"><span class="glyph">●</span>In a randomized trial, 1161 people with mild to moderate hypertension were randomly assigned to <a class="drug drug_general" data-topicid="9574" href="/d/drug information/9574.html" rel="external">losartan</a>, <a class="drug drug_general" data-topicid="8670" href="/d/drug information/8670.html" rel="external">candesartan</a>, or losartan plus <a class="drug drug_general" data-topicid="8529" href="/d/drug information/8529.html" rel="external">hydrochlorothiazide</a> [<a href="#rid40">40</a>]. At 12 weeks, serum urate levels had decreased, stayed the same, or increased in those administered losartan, losartan plus thiazide, and candesartan, respectively. The combination of losartan plus the thiazide also provided superior blood pressure control to monotherapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a randomized trial that compared <a class="drug drug_general" data-topicid="9574" href="/d/drug information/9574.html" rel="external">losartan</a> with <a class="drug drug_general" data-topicid="9405" href="/d/drug information/9405.html" rel="external">enalapril</a>, losartan but not enalapril lowered serum urate levels; there were no other metabolic differences between the two drugs [<a href="#rid41">41</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a small prospective study, four weeks of <a class="drug drug_general" data-topicid="9574" href="/d/drug information/9574.html" rel="external">losartan</a> decreased serum urate levels by 9 percent, while <a class="drug drug_general" data-topicid="8640" href="/d/drug information/8640.html" rel="external">irbesartan</a> had no effect [<a href="#rid42">42</a>]. The effect of losartan was seen at a dose of 50 mg once daily with no further reduction at a dose of 50 mg twice daily.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In an in vitro study, <a class="drug drug_general" data-topicid="9574" href="/d/drug information/9574.html" rel="external">losartan</a>, but not other ARBs, inhibited the renal urate anion exchanger (URAT1) that partially mediates urate reabsorption [<a href="#rid10">10</a>].</p><p></p><p>Although uric acid excretion is initially increased, there appears to be little risk of uric acid nephropathy with <a class="drug drug_general" data-topicid="9574" href="/d/drug information/9574.html" rel="external">losartan</a> because of a concurrent elevation in urine pH due to reduced bicarbonate reabsorption [<a href="#rid38">38</a>]. As a result, there is little or no increase in the urinary excretion of insoluble undissociated uric acid; urinary urate excretion rises but this is associated with little stone potential. A new steady state for uric acid is achieved within seven days as uric acid excretion returns to baseline levels. (See  <a class="medical medical_review" href="/d/html/7379.html" rel="external">"Uric acid kidney diseases"</a>.)</p><p>The combination of <a class="drug drug_general" data-topicid="9574" href="/d/drug information/9574.html" rel="external">losartan</a> or an ACE inhibitor with a thiazide has the added advantages of a more potent antihypertensive effect than seen with either drug alone and of minimizing other metabolic effects of the diuretic, such as hypokalemia and hyperlipidemia [<a href="#rid18">18,37</a>]. (See  <a class="medical medical_review" href="/d/html/3815.html" rel="external">"Renin-angiotensin system inhibition in the treatment of hypertension"</a>.)</p><p class="headingAnchor" id="H2964517253"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/109601.html" rel="external">"Society guideline links: Hypertension in adults"</a>.)</p><p class="headingAnchor" id="H533507"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Hyperuricemia is a relatively common finding in people treated with a loop or thiazide diuretic and may lead, over time, to new-onset gout and, in people with already established gout, more frequent occurrence of gout flares. The degree of urate retention caused by diuretics is dose dependent  (<a class="graphic graphic_figure graphicRef69912" href="/d/graphic/69912.html" rel="external">figure 1</a>). (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Loop and thiazide diuretics decrease urate excretion by increasing net urate reabsorption; this can occur either by enhanced reabsorption or by reduced secretion. Two mechanisms have been proposed as contributing to diuretic-induced hyperuricemia (see <a class="local">'Pathogenesis'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A direct effect of diuretics on promoting urate reabsorption by the proximal tubule. (See <a class="local">'Direct effect of diuretics'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>An indirect effect of diuretic-induced volume depletion on increasing urate reabsorption by the proximal tubule. (See <a class="local">'Indirect effect of diuretic-induced volume depletion'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diuretics may increase the relative risk of gout by nearly 80 percent; the absolute incidence of gout in people taking diuretics may be close to 3 percent. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A diagnosis of gout is not necessarily an indication for discontinuation of the diuretic. However, if blood pressure control can be effectively and affordably achieved with an appropriate alternative agent, such as an angiotensin inhibitor or a dihydropyridine calcium channel blocker, then the diuretic should be replaced with an alternate agent. (See <a class="local">'Overview of treatment and benefits of angiotensin inhibition'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Most people with diuretic-induced gout are treated with a urate-lowering drug such as <a class="drug drug_general" data-topicid="8439" href="/d/drug information/8439.html" rel="external">allopurinol</a>. Treatment of diuretic-induced asymptomatic hyperuricemia is not recommended. (See <a class="local">'Overview of treatment and benefits of angiotensin inhibition'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among people with hypertension, the concurrent administration of an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB), particularly <a class="drug drug_general" data-topicid="9574" href="/d/drug information/9574.html" rel="external">losartan</a>, can minimize the diuretic-induced rise in serum urate concentration. The combination of losartan or an ACE inhibitor with a thiazide has the added advantages of a more potent antihypertensive effect than seen with either drug alone and of minimizing other metabolic effects of the diuretic, such as hypokalemia and hyperlipidemia. (See <a class="local">'Benefits of angiotensin inhibition and losartan'</a> above.)</p><p></p><p class="headingAnchor" id="H3015021337"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Michael A Becker, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Langford HG, Blaufox MD, Borhani NO, et al. Is thiazide-produced uric acid elevation harmful? Analysis of data from the Hypertension Detection and Follow-up Program. Arch Intern Med 1987; 147:645.</a></li><li><a class="nounderline abstract_t">Kahn AM. Effect of diuretics on the renal handling of urate. Semin Nephrol 1988; 8:305.</a></li><li><a class="nounderline abstract_t">Choi HK, Atkinson K, Karlson EW, Curhan G. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. Arch Intern Med 2005; 165:742.</a></li><li><a class="nounderline abstract_t">Choi HK, Soriano LC, Zhang Y, Rodríguez LA. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. BMJ 2012; 344:d8190.</a></li><li><a class="nounderline abstract_t">Hunter DJ, York M, Chaisson CE, et al. Recent diuretic use and the risk of recurrent gout attacks: the online case-crossover gout study. J Rheumatol 2006; 33:1341.</a></li><li><a class="nounderline abstract_t">Weinman EJ, Eknoyan G, Suki WN. The influence of the extracellular fluid volume on the tubular reabsorption of uric acid. J Clin Invest 1975; 55:283.</a></li><li><a class="nounderline abstract_t">Hagos Y, Stein D, Ugele B, et al. Human renal organic anion transporter 4 operates as an asymmetric urate transporter. J Am Soc Nephrol 2007; 18:430.</a></li><li><a class="nounderline abstract_t">El-Sheikh AA, van den Heuvel JJ, Koenderink JB, Russel FG. Effect of hypouricaemic and hyperuricaemic drugs on the renal urate efflux transporter, multidrug resistance protein 4. Br J Pharmacol 2008; 155:1066.</a></li><li><a class="nounderline abstract_t">Mandal AK, Mount DB. The molecular physiology of uric acid homeostasis. Annu Rev Physiol 2015; 77:323.</a></li><li><a class="nounderline abstract_t">Enomoto A, Kimura H, Chairoungdua A, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 2002; 417:447.</a></li><li><a class="nounderline abstract_t">Dalbeth N, Merriman T. Crystal ball gazing: new therapeutic targets for hyperuricaemia and gout. Rheumatology (Oxford) 2009; 48:222.</a></li><li><a class="nounderline abstract_t">Hosomi A, Nakanishi T, Fujita T, Tamai I. Extra-renal elimination of uric acid via intestinal efflux transporter BCRP/ABCG2. PLoS One 2012; 7:e30456.</a></li><li><a class="nounderline abstract_t">Iharada M, Miyaji T, Fujimoto T, et al. Type 1 sodium-dependent phosphate transporter (SLC17A1 Protein) is a Cl(-)-dependent urate exporter. J Biol Chem 2010; 285:26107.</a></li><li><a class="nounderline abstract_t">Jutabha P, Anzai N, Kitamura K, et al. Human sodium phosphate transporter 4 (hNPT4/SLC17A3) as a common renal secretory pathway for drugs and urate. J Biol Chem 2010; 285:35123.</a></li><li><a class="nounderline abstract_t">Russel FG, Koenderink JB, Masereeuw R. Multidrug resistance protein 4 (MRP4/ABCC4): a versatile efflux transporter for drugs and signalling molecules. Trends Pharmacol Sci 2008; 29:200.</a></li><li><a class="nounderline abstract_t">Eraly SA, Vallon V, Rieg T, et al. Multiple organic anion transporters contribute to net renal excretion of uric acid. Physiol Genomics 2008; 33:180.</a></li><li><a class="nounderline abstract_t">Caulfield MJ, Munroe PB, O'Neill D, et al. SLC2A9 is a high-capacity urate transporter in humans. PLoS Med 2008; 5:e197.</a></li><li><a class="nounderline abstract_t">Carlsen JE, Køber L, Torp-Pedersen C, Johansen P. Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. BMJ 1990; 300:975.</a></li><li><a class="nounderline abstract_t">Nijenhuis T, Vallon V, van der Kemp AW, et al. Enhanced passive Ca2+ reabsorption and reduced Mg2+ channel abundance explains thiazide-induced hypocalciuria and hypomagnesemia. J Clin Invest 2005; 115:1651.</a></li><li><a class="nounderline abstract_t">Steele TH, Oppenheimer S. Factors affecting urate excretion following diuretic administration in man. Am J Med 1969; 47:564.</a></li><li><a class="nounderline abstract_t">Page LB, Damon A, Moellering RC Jr. Antecedents of cardiovascular disease in six Solomon Islands societies. Circulation 1974; 49:1132.</a></li><li><a class="nounderline abstract_t">Egan BM, Lackland DT. Biochemical and metabolic effects of very-low-salt diets. Am J Med Sci 2000; 320:233.</a></li><li><a class="nounderline abstract_t">Masugi F, Ogihara T, Hashizume K, et al. Changes in plasma lipids and uric acid with sodium loading and sodium depletion in patients with essential hypertension. J Hum Hypertens 1988; 1:293.</a></li><li><a class="nounderline abstract_t">Del Río A, Rodríguez-Villamil JL. Metabolic effects of strict salt restriction in essential hypertensive patients. J Intern Med 1993; 233:409.</a></li><li><a class="nounderline abstract_t">Skrabal F, Auböck J, Hörtnagl H. Low sodium/high potassium diet for prevention of hypertension: probable mechanisms of action. Lancet 1981; 2:895.</a></li><li><a class="nounderline abstract_t">Ruppert M, Diehl J, Kolloch R, et al. Short-term dietary sodium restriction increases serum lipids and insulin in salt-sensitive and salt-resistant normotensive adults. Klin Wochenschr 1991; 69 Suppl 25:51.</a></li><li><a class="nounderline abstract_t">Kahn AM. Indirect coupling between sodium and urate transport in the proximal tubule. Kidney Int 1989; 36:378.</a></li><li><a class="nounderline abstract_t">Cogan MG. Angiotensin II: a powerful controller of sodium transport in the early proximal tubule. Hypertension 1990; 15:451.</a></li><li><a class="nounderline abstract_t">Bruderer S, Bodmer M, Jick SS, Meier CR. Use of diuretics and risk of incident gout: a population-based case-control study. Arthritis Rheumatol 2014; 66:185.</a></li><li><a class="nounderline abstract_t">Mitnala S, Phipps-Green A, Franklin C, et al. Clinical and genetic features of diuretic-associated gout: a case-control study. Rheumatology (Oxford) 2016; 55:1172.</a></li><li><a class="nounderline abstract_t">Liang MH, Fries JF. Asymptomatic hyperuricemia: the case for conservative management. Ann Intern Med 1978; 88:666.</a></li><li><a class="nounderline abstract_t">Buscemi S, Buscemi C, Borzì AM, et al. Metabolic and Cardiovascular Effects of Switching Thiazides to Amlodipine in Hypertensive Patients With and Without Type 2 Diabetes (the Diuretics and Diabetes Control Study). Metab Syndr Relat Disord 2020; 18:110.</a></li><li><a class="nounderline abstract_t">Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984; 76:47.</a></li><li><a class="nounderline abstract_t">Stamp LK, O'Donnell JL, Zhang M, et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum 2011; 63:412.</a></li><li><a class="nounderline abstract_t">Stamp LK, Chapman PT, Barclay ML, et al. A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout. Ann Rheum Dis 2017; 76:1522.</a></li><li><a class="nounderline abstract_t">Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 2012; 64:1431.</a></li><li><a class="nounderline abstract_t">Weinberger MH. Influence of an angiotensin converting-enzyme inhibitor on diuretic-induced metabolic effects in hypertension. Hypertension 1983; 5:III132.</a></li><li><a class="nounderline abstract_t">Shahinfar S, Simpson RL, Carides AD, et al. Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia. Kidney Int 1999; 56:1879.</a></li><li><a class="nounderline abstract_t">Soffer BA, Wright JT Jr, Pratt JH, et al. Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension 1995; 26:112.</a></li><li><a class="nounderline abstract_t">Manolis AJ, Grossman E, Jelakovic B, et al. Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension. Losartan Trial Investigators. Clin Ther 2000; 22:1186.</a></li><li><a class="nounderline abstract_t">Tikkanen I, Omvik P, Jensen HA. Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension. J Hypertens 1995; 13:1343.</a></li><li><a class="nounderline abstract_t">Würzner G, Gerster JC, Chiolero A, et al. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. J Hypertens 2001; 19:1855.</a></li></ol></div><div id="topicVersionRevision">Topic 2380 Version 17.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3827451" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Is thiazide-produced uric acid elevation harmful? Analysis of data from the Hypertension Detection and Follow-up Program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3059433" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Effect of diuretics on the renal handling of urate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15824292" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22240117" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16758506" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Recent diuretic use and the risk of recurrent gout attacks: the online case-crossover gout study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1127100" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The influence of the extracellular fluid volume on the tubular reabsorption of uric acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17229912" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Human renal organic anion transporter 4 operates as an asymmetric urate transporter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18724382" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Effect of hypouricaemic and hyperuricaemic drugs on the renal urate efflux transporter, multidrug resistance protein 4.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25422986" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The molecular physiology of uric acid homeostasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12024214" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Molecular identification of a renal urate anion exchanger that regulates blood urate levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19109320" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Crystal ball gazing: new therapeutic targets for hyperuricaemia and gout.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22348008" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Extra-renal elimination of uric acid via intestinal efflux transporter BCRP/ABCG2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20566650" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Type 1 sodium-dependent phosphate transporter (SLC17A1 Protein) is a Cl(-)-dependent urate exporter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20810651" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Human sodium phosphate transporter 4 (hNPT4/SLC17A3) as a common renal secretory pathway for drugs and urate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18353444" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Multidrug resistance protein 4 (MRP4/ABCC4): a versatile efflux transporter for drugs and signalling molecules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18270321" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Multiple organic anion transporters contribute to net renal excretion of uric acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18842065" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : SLC2A9 is a high-capacity urate transporter in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2344503" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15902302" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Enhanced passive Ca2+ reabsorption and reduced Mg2+ channel abundance explains thiazide-induced hypocalciuria and hypomagnesemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4309843" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Factors affecting urate excretion following diuretic administration in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4831656" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Antecedents of cardiovascular disease in six Solomon Islands societies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11061347" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Biochemical and metabolic effects of very-low-salt diets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3221377" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Changes in plasma lipids and uric acid with sodium loading and sodium depletion in patients with essential hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8487006" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Metabolic effects of strict salt restriction in essential hypertensive patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6117684" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Low sodium/high potassium diet for prevention of hypertension: probable mechanisms of action.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1921253" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Short-term dietary sodium restriction increases serum lipids and insulin in salt-sensitive and salt-resistant normotensive adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2687564" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Indirect coupling between sodium and urate transport in the proximal tubule.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2185149" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Angiotensin II: a powerful controller of sodium transport in the early proximal tubule.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24449584" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Use of diuretics and risk of incident gout: a population-based case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26989110" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Clinical and genetic features of diuretic-associated gout: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/646260" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Asymptomatic hyperuricemia: the case for conservative management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31976814" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Metabolic and Cardiovascular Effects of Switching Thiazides to Amlodipine in Hypertensive Patients With and Without Type 2 Diabetes (the Diuretics and Diabetes Control Study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6691361" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21279998" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28314755" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23024028" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6313523" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Influence of an angiotensin converting-enzyme inhibitor on diuretic-induced metabolic effects in hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10571797" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7607713" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Effects of losartan on a background of hydrochlorothiazide in patients with hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11110230" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension. Losartan Trial Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8984133" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11593107" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
